We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$482M
AUM Growth
-$151M
Cap. Flow
-$70.7M
Cap. Flow %
-14.68%
Top 10 Hldgs %
78.28%
Holding
34
New
5
Increased
8
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$15.5M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$11.7M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$11.3M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$9.29M
5
PRQR icon
ProQR Therapeutics
PRQR
+$8.8M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$49.4M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$41.7M
3
EXEL icon
Exelixis
EXEL
+$3.39M
4
ARRY
Array Biopharma Inc
ARRY
+$3.31M
5
QLTI
QLT Inc
QLTI
+$1.56M

Sector Composition

Rank Sector Weight
1 Healthcare 65.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$614M
$72.5M 15.06%
6,682,896
-4,312,541
-39% -$49.4M
RCPT
2
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$71.2M 14.78%
1,146,300
+235,700
+26% +$11.3M
LGND icon
3
Ligand Pharmaceuticals
LGND
$5.94B
$52.1M 10.82%
1,777,347
-1,257,329
-41% -$41.7M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$49.5M 10.29%
13,876,513
-839,273
-6% -$3.31M
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
$38.7M 8.03%
8,596,772
+414,956
+5% +$2.19M
OMED
6
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$24.4M 5.06%
1,287,847
+462,200
+56% +$9.29M
CASC
7
DELISTED
Cascadian Therapeutics, Inc.
CASC
$18.9M 3.93%
1,644,546
+1,500
+0.1% +$22.9K
FPRX
8
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$17.1M 3.56%
1,461,900
+208,900
+17% +$2.64M
GYRE icon
9
Gyre Therapeutics
GYRE
$648M
$16.8M 3.5%
8,451
– –
LOXO
10
DELISTED
Loxo Oncology, Inc
LOXO
$15.7M 3.25%
+1,192,202
New +$15.5M
CNCE
11
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$15.2M 3.16%
+1,206,459
New +$11.7M
QLTI
12
DELISTED
QLT Inc
QLTI
$9.46M 1.96%
2,093,563
-276,700
-12% -$1.56M
PRQR icon
13
ProQR Therapeutics
PRQR
$251M
$9.44M 1.96%
+549,000
New +$8.8M
TRVN
14
DELISTED
Trevena, Inc.
TRVN
$7.18M 1.49%
1,790
– –
ARDX icon
15
Ardelyx
ARDX
$1.25B
$6.45M 1.34%
+453,541
New +$6.56M
CYTK icon
16
Cytokinetics
CYTK
$10.9B
$5.38M 1.12%
1,527,000
+210,000
+16% +$882K
VTAE
17
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$5.08M 1.06%
+666,000
New +$5.18M
ARQL
18
DELISTED
Arqule Inc
ARQL
$4.82M 1%
4,300,887
+1,176,000
+38% +$1.55M
TBRA
19
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.95M 0.61%
289,677
– –
BLRX
20
BioLineRX
BLRX
$11.7M
$2.31M 0.48%
2,502
– –
KBIO
21
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
$1.8M 0.37%
145,250
– –
ACHV icon
22
Achieve Life Sciences
ACHV
$647M
$1.77M 0.37%
301
-91
-23% -$632K
SPHS
23
DELISTED
Sophiris Bio, Inc.
SPHS
$1.76M 0.37%
600,000
– –
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$1.26M 0.26%
1,542
– –
AKAO
25
DELISTED
Achaogen Inc
AKAO
$1.22M 0.25%
136,600
+11,600
+9% +$119K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2014 Portfolio in Review

As of Q3 2014, BVF Inc held 34 positions worth $482M, down 24% from $632M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

BVF Inc withdrew a net $70.7M in Q3 2014, closing 2 positions and reducing 7 holdings. Its most notable exit was Exelixis, an estimated $3.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 76% a quarter earlier.

Against the trend, BVF Inc opened a new position in Loxo Oncology, Inc worth $15.7M.

  • BVF Inc's largest Q3 2014 buy was Loxo Oncology, Inc: 1,192,202 shares worth $15.7M.
  • BVF Inc added most to RECEPTOS INC COM STK (DE) in Q3 2014, an estimated $11.3M increase.
  • BVF Inc's biggest Q3 2014 reduction was Ironwood Pharmaceuticals, cutting an estimated $49.4M.
  • BVF Inc fully exited Exelixis in Q3 2014, selling an estimated $3.39M.
  • BVF Inc's ten largest holdings make up 78% of its $482M portfolio in Q3 2014.
  • BVF Inc opened 5 new positions and closed 2 in Q3 2014.
  • BVF Inc's portfolio value fell 24% quarter-over-quarter to $482M.

Based on BVF Inc's 13F filing for Q3 2014, filed 14 Nov 2014.